Quotes are at least 15-min delayed:2026/07/16 19:14 EDT
After Hours
|
||||
|
316.89 
|
|
|
Regular Hours (Closed)
|
|
|
|
|
||||||||||||
|
|
|
|
|
317.42
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
4.42/8.31
|
|
Enterprise Value
33.31B
|
| Balance Sheet |
|
Book Value Per Share
45.88
|
| Cash Flow |
|
Cash Flow Yield
0.04
|
| Income Statement |
|
Total Revenue
5.34B
|
|
Operating Revenue Per Share
--
|
|
Industry Comparison
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
|
Business Description
|
|||
| Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers. |
